Circulating Levels of Tissue Inhibitor of Metalloproteinase 3, a Protein with Inhibitory Effects on Angiogenesis, Are Increased in Pre-eclampsia

Overview

Journal Int J Gynaecol Obstet

Publisher Wiley

Specialty Gynecology & Obstetrics

Date 2022 Nov 5

PMID 36333976

Authors

Ana C Palei

Juliana de O Cruz

Joao Leandro Chaguri

Jose Carlos Peracoli

Mariana Romao-Veiga

Vanessa R Ribeiro-Vasques

Ricardo C Cavalli

Priscila R Nunes

Marcelo R Luizon

Valeria C Sandrim

Affiliations

Soon will be listed here.

Abstract

Objective: To assess and compare circulating tissue inhibitor of metalloproteinase 3 (TIMP-3) concentrations between women with pre-eclampsia and healthy pregnant women. We also aimed to determine the relationships between circulating TIMP-3 and matrix metalloproteinase 2 (MMP-2), MMP-9, TIMP-1, and TIMP-2 concentrations in pre-eclampsia.

Methods: A primary case-control study included patients with pre-eclampsia (n = 219) and gestational hypertension (n = 118), healthy pregnant women (n = 214), and non-pregnant women (n = 66), and a replication case-control study included patients with pre-eclampsia (n = 177) and healthy pregnant women (n = 124), all from southeastern Brazil. Plasma TIMP-3, MMP-2, MMP-9, TIMP-1, and TIMP-2 concentrations were assessed using commercially available enzyme-linked immunosorbent assay kits, and the relationships between them were analyzed using Spearman's correlation.

Results: In our primary study, patients with pre-eclampsia and gestational hypertension exhibited increased TIMP-3 concentrations compared with healthy pregnant women (both P < 0.0001) and non-pregnant women (both P < 0.001). These findings were confirmed in the replication study, showing elevated TIMP-3 concentrations in women with pre-eclampsia versus healthy pregnant women (P < 0.001). We found no difference in TIMP-3 concentrations between early-onset and late-onset pre-eclampsia. Moreover, TIMP-3 concentrations were significantly correlated with plasma concentrations of TIMP-1 (r = 0.2333; P = 0.0086) and MMP-2 (r = 0.2159; P = 0.0156) in pre-eclampsia.

Conclusions: Circulating TIMP-3 concentration is increased in women with pre-eclampsia compared with healthy pregnant women, and it is positively correlated with plasma MMP-2 and TIMP-1 concentrations in pre-eclampsia.

Citing Articles

Potential epigenetic markers of clinical diagnostics/therapeutic targets in preeclampsia.

de Oliveira Cruz J, Luizon M Epigenomics. 2024; 16(15-16):1057-1060.

PMID: 39115080 PMC: 11418293. DOI: 10.1080/17501911.2024.2383558.

Antihypertensive therapy responsiveness and adverse outcomes in preeclampsia: insights into molecular mechanisms underlying cardiovascular and renal complications.

Luizon M, Pereira D, Mamede I, Ceron C, Cavalli R, Palei A Front Pharmacol. 2023; 14:1281382.

PMID: 38074158 PMC: 10702581. DOI: 10.3389/fphar.2023.1281382.

Understanding the Role of Chemerin in the Pathophysiology of Pre-Eclampsia.

Pankiewicz K, Issat T Antioxidants (Basel). 2023; 12(4).

PMID: 37107205 PMC: 10135338. DOI: 10.3390/antiox12040830.

References

Sandrim V, Diniz S, Eleuterio N, Gomes K, Dusse L, Cavalli R . Higher levels of circulating TIMP-4 in preeclampsia is strongly associated with clinical parameters and microRNA. Clin Exp Hypertens. 2017; 40(7):609-612. DOI: 10.1080/10641963.2017.1411499. View

Uhlen M, Fagerberg L, Hallstrom B, Lindskog C, Oksvold P, Mardinoglu A . Proteomics. Tissue-based map of the human proteome. Science. 2015; 347(6220):1260419. DOI: 10.1126/science.1260419. View

Palei A, Sandrim V, Amaral L, Machado J, Cavalli R, Duarte G . Association between matrix metalloproteinase (MMP)-2 polymorphisms and MMP-2 levels in hypertensive disorders of pregnancy. Exp Mol Pathol. 2012; 92(2):217-21. DOI: 10.1016/j.yexmp.2012.01.008. View

Cruz J, Conceicao I, Sandrim V, Luizon M . Comprehensive analyses of DNA methylation of the TIMP3 promoter in placentas from early-onset and late-onset preeclampsia. Placenta. 2021; 117:118-121. DOI: 10.1016/j.placenta.2021.12.003. View

Karthikeyan V, Lane D, Beevers D, Lip G, Blann A . Matrix metalloproteinases and their tissue inhibitors in hypertension-related pregnancy complications. J Hum Hypertens. 2012; 27(2):72-8. DOI: 10.1038/jhh.2012.8. View

Cruz J, Conceicao I, Tosatti J, Gomes K, Luizon M . Global DNA methylation in placental tissues from pregnant with preeclampsia: A systematic review and pathway analysis. Placenta. 2020; 101:97-107. DOI: 10.1016/j.placenta.2020.09.004. View

Luizon M, Palei A, Sandrim V, Amaral L, Machado J, Lacchini R . Tissue inhibitor of matrix metalloproteinase-1 polymorphism, plasma TIMP-1 levels, and antihypertensive therapy responsiveness in hypertensive disorders of pregnancy. Pharmacogenomics J. 2014; 14(6):535-41. DOI: 10.1038/tpj.2014.26. View

Spradley F, Palei A, Granger J . Increased risk for the development of preeclampsia in obese pregnancies: weighing in on the mechanisms. Am J Physiol Regul Integr Comp Physiol. 2015; 309(11):R1326-43. PMC: 4698403. DOI: 10.1152/ajpregu.00178.2015. View

Sandrim V, Palei A, Metzger I, Gomes V, Cavalli R, Tanus-Santos J . Nitric oxide formation is inversely related to serum levels of antiangiogenic factors soluble fms-like tyrosine kinase-1 and soluble endogline in preeclampsia. Hypertension. 2008; 52(2):402-7. DOI: 10.1161/HYPERTENSIONAHA.108.115006. View

10.

Palei A, Sandrim V, Amaral L, Machado J, Cavalli R, Lacchini R . Matrix metalloproteinase-9 polymorphisms affect plasma MMP-9 levels and antihypertensive therapy responsiveness in hypertensive disorders of pregnancy. Pharmacogenomics J. 2011; 12(6):489-98. DOI: 10.1038/tpj.2011.31. View

11.

Zhao H, Bernardo M, Osenkowski P, Sohail A, Pei D, Nagase H . Differential inhibition of membrane type 3 (MT3)-matrix metalloproteinase (MMP) and MT1-MMP by tissue inhibitor of metalloproteinase (TIMP)-2 and TIMP-3 rgulates pro-MMP-2 activation. J Biol Chem. 2003; 279(10):8592-601. DOI: 10.1074/jbc.M308708200. View

12.

Rana S, Lemoine E, Granger J, Karumanchi S . Preeclampsia: Pathophysiology, Challenges, and Perspectives. Circ Res. 2019; 124(7):1094-1112. DOI: 10.1161/CIRCRESAHA.118.313276. View

13.

Cabral-Pacheco G, Garza-Veloz I, Castruita-De la Rosa C, Ramirez-Acuna J, Perez-Romero B, Guerrero-Rodriguez J . The Roles of Matrix Metalloproteinases and Their Inhibitors in Human Diseases. Int J Mol Sci. 2021; 21(24). PMC: 7767220. DOI: 10.3390/ijms21249739. View

14.

Xiang Y, Zhang X, Li Q, Xu J, Zhou X, Wang T . Promoter hypomethylation of TIMP3 is associated with pre-eclampsia in a Chinese population. Mol Hum Reprod. 2012; 19(3):153-9. DOI: 10.1093/molehr/gas054. View

15.

Ahonen M, Poukkula M, Baker A, Kashiwagi M, Nagase H, Eriksson J . Tissue inhibitor of metalloproteinases-3 induces apoptosis in melanoma cells by stabilization of death receptors. Oncogene. 2003; 22(14):2121-34. DOI: 10.1038/sj.onc.1206292. View

16.

Palei A, Granger J, Tanus-Santos J . Matrix metalloproteinases as drug targets in preeclampsia. Curr Drug Targets. 2013; 14(3):325-34. PMC: 3675769. DOI: 10.2174/1389450111314030004. View

17.

. Female Sexual Dysfunction: ACOG Practice Bulletin Clinical Management Guidelines for Obstetrician-Gynecologists, Number 213. Obstet Gynecol. 2019; 134(1):e1-e18. DOI: 10.1097/AOG.0000000000003324. View

18.

Montagnana M, Lippi G, Albiero A, Scevarolli S, Salvagno G, Franchi M . Evaluation of metalloproteinases 2 and 9 and their inhibitors in physiologic and pre-eclamptic pregnancy. J Clin Lab Anal. 2009; 23(2):88-92. PMC: 6649012. DOI: 10.1002/jcla.20295. View

19.

von Dadelszen P, Magee L, Roberts J . Subclassification of preeclampsia. Hypertens Pregnancy. 2003; 22(2):143-8. DOI: 10.1081/PRG-120021060. View

20.

Nunes P, Romao-Veiga M, Peracoli J, Araujo Costa R, de Oliveira L, Borges V . Downregulation of CD163 in monocytes and its soluble form in the plasma is associated with a pro-inflammatory profile in pregnant women with preeclampsia. Immunol Res. 2019; 67(2-3):194-201. DOI: 10.1007/s12026-019-09078-8. View